Full Management and Board Subscribes to the Warrant Program Adopted by the AGM
24 juni, 14:20
Full Management and Board Subscribes to the Warrant Program Adopted by the AGM
Scandinavian Chemotech AB announces that the entire management team and board of directors have fully subscribed to the warrant programs approved by shareholders at the Annual General Meeting held on 13 May 2024.
The warrant program includes 470,000 warrants allocated to management and 690,000 to the board of directors. Both programs have been fully subscribed, underscoring the strong alignment of interests between company leadership and shareholders.
“This is a clear signal of commitment and confidence from both our board and management in the future of Scandinavian ChemoTech,” said Robin Sukhia, Chairman. “The participation serves as a quality stamp for the company and reflects the shared belief in our long-term vision and growth potential.”
The Strike Price for the warrants is 4,50 SEK with a subscription period between1 September 2028 and 31 October 2028. The valuation was made by a third party using the Black and Scholes model to make the program neutral from any discounts or taxable benefits.
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.
For further information please contact:
Mohan Frick, CEO
Phone: +46 (0)10-218 93 00
E-mail: ir@chemotech.se
Ämnen i artikeln
Full Management and Board Subscribes to the Warrant Program Adopted by the AGM
24 juni, 14:20
Full Management and Board Subscribes to the Warrant Program Adopted by the AGM
Scandinavian Chemotech AB announces that the entire management team and board of directors have fully subscribed to the warrant programs approved by shareholders at the Annual General Meeting held on 13 May 2024.
The warrant program includes 470,000 warrants allocated to management and 690,000 to the board of directors. Both programs have been fully subscribed, underscoring the strong alignment of interests between company leadership and shareholders.
“This is a clear signal of commitment and confidence from both our board and management in the future of Scandinavian ChemoTech,” said Robin Sukhia, Chairman. “The participation serves as a quality stamp for the company and reflects the shared belief in our long-term vision and growth potential.”
The Strike Price for the warrants is 4,50 SEK with a subscription period between1 September 2028 and 31 October 2028. The valuation was made by a third party using the Black and Scholes model to make the program neutral from any discounts or taxable benefits.
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.
For further information please contact:
Mohan Frick, CEO
Phone: +46 (0)10-218 93 00
E-mail: ir@chemotech.se
Ämnen i artikeln
-992x558.webp&w=3840&q=75)
Aktierekommendationer
Analyser
-160x160.jpg&w=3840&q=75)
Oljepriset
-992x558.png&w=3840&q=75)
.jpg&w=3840&q=75)
Mest läst
Aktierekommendationer
Analyser
Oljepriset
Marknadsöversikt
1 DAG %
Senast
1 mån
Privatekonomi med Placeras expert
Affärsvärlden
